Login

Financial Snapshot

Revenue
TTM
$1.707B
Gross Margin
TTM
40.45%
Net Income
TTM
-$402.2M
Current Assets
2026 Q1
Current Liabilities
2026 Q1
Current Ratio
2026 Q1
300.6%
Total Assets
2026 Q1
Total Liabilities
2026 Q1
Book Value
2026 Q1
$1.958B
Cash
2026 Q1
P/E
Last 4 Quarters
N/A
Free Cash Flow
Last 4 Quarters
N/A

Stock Price

Loading...
Market Cap: $1.383 Million

About Keenova Therapeutics plc

Mallinckrodt Plc engages in the development, manufacture, market, adn distribution of both branded and generic specialty pharmaceutical products and medical imaging agents. The firm operates in two reportable segments: Specialty Brands and Specialty Generics. The Specialty Brands includes specialty pharmaceutical brands. The Specialty Generics includes niche specialty generic drugs and active pharmaceutical ingredients. Its Specialty Generics segment is focused on providing its customers with specialty generic drugs and active pharmaceutical ingredients (APIs). The firm focuses on various therapeutic areas, such as autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics, cultured skin substitutes and gastrointestinal products. Its product portfolio includes Acthar Gel, INOmax, Therakos photopheresis, StrataGraft, Terlivaz, and Amitiza.

Industry: Pharmaceutical Preparations Peers: AVADEL PHARMACEUTICALS PLC Endo International plc GH Research PLC /entities/itrm Jazz Pharmaceuticals PLC Nabriva Therapeutics plc Perrigo Company PLC

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support